Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921205 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT01921205 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 404 participants.
The verdict
NCT01921205, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to \<17 years of age who currently have uncontrolled partial onset seizures.
Interventions
- OTHER Placebo
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2013-08-29 |
| Est. Completion | 2017-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01921205
The ClinicalTrials.gov registry entry for NCT01921205 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01921205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01921205 about?
NCT01921205 is a clinical study titled "Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures". Study to evaluate the efficacy of Lacosamide (LCM) administered in addition to 1 to ≤3 other Anti-Epileptic Drugs in subjects with epilepsy ≥4 years to \<17 years of age who currently have uncontrolled partial onset seizures.
What is the current status of trial NCT01921205?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2013-08-29. Estimated completion is 2017-01-24.
What interventions are being tested in trial NCT01921205?
The interventions under investigation include: Placebo (OTHER), Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01921205?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.